Tarlatamab - Is Imdelltra currently on the market?

Tarlatamab-Imdelltra is an innovative bispecific antibody drug specifically developed for patients with extensive-stage small cell lung cancer (ES-SCLC). Its unique mechanism of action has attracted great attention clinically. According to the latest overseas information, the U.S. Food and Drug Administration (FDA) has approved the marketing of Imdelltra on May 16, 2024, for the treatment of adult patients with ES-SCLC whose disease has progressed during or after platinum-based chemotherapy. This marks Talatumumab as one of the first bispecific antibody therapies for this type of refractory lung cancer, providing patients with a new treatment option.

Currently, the drug has not been approved for marketing in other countries and regions, which means that accessibility in the international market remains limited. Clinical trial data supports its efficacy in patients with disease progression, showing that talatumumab can activate T cells to directly recognize and kill cancer cells, thereby achieving targeted therapy for tumors. The significance of its launch is not only to provide new treatment options, but also to provide new clinical data support for global lung cancer research, while promoting the application and development of immune bispecific antibody drugs in the field of cancer.

In the domestic market, since it has not yet been launched, patients cannot obtain the drug through formal domestic channels. Therefore, its use still needs to wait for official approval and release of marketing information. During the waiting period, doctors and scientific research institutions can refer to international clinical data to conduct research and explore treatment strategies, but patients must not obtain or use unapproved drugs on their own to avoid uncontrollable safety risks. The launch of talatumumab not only fills the gap in the treatment of extensive-stage small cell lung cancer, but also marks a new breakthrough in targeted immunotherapy in refractory lung cancer.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html